Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.

PloS one - 1 Jan 2012

Brandi Giovanni, Tavolari Simona, De Rosa Francesco, Di Girolamo Stefania, Agostini Valentina, Barbera Maria Aurelia, Frega Giorgio, Biasco Guido

Abstract excerpt

The employment of anti-epidermal growth factor receptor (EGFR) antibodies represents a backbone of the therapeutic options for the treatment of metastatic colorectal cancer (mCRC). However, this therapy is poorly effective or ineffective in unselected patients. Mutations in KRAS, BRAF and PIK3CA genes have recently emerged as the best predictive factors of low/absent response to EGFR-targeted therapy. Due to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Colonic Neoplasms

Share to Culture Media, Conditioned

Share to Neoplasm Invasiveness

Share to Neovascularization, Pathologic

Share to Protease Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 22911782
DOI: 10.1371/journal.pone.0041347
PMCID: PMC3404056

Genes

BRAF
KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.PMID 22911782Read ↗

Panitumumab in the treatment of colon cancer: A biomarker dilemma.Semantic proximity Read ↗

EGFR and colon cancer: a clinical view.Semantic proximity Read ↗

The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.Semantic proximity Read ↗

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.Semantic proximity Read ↗

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.Semantic proximity Read ↗

Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.Semantic proximity Read ↗

4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.Semantic proximity Read ↗

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.Semantic proximity Read ↗

PI-3-Kinase inhibitors in colorectal cancer.Semantic proximity Read ↗

Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.Semantic proximity Read ↗

Epithelial-to-Mesenchymal Transition and Oncogenic Ras Expression in Resistance to the Protein Kinase Cβ Inhibitor Enzastaurin in Colon Cancer CellsSemantic proximity Read ↗

Targeting the PI3K signaling pathway in KRAS mutant colon cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.